Assertio Holdings, Inc. ("Assertio" or the "Company") today announced that results of a clinical trial investigating a novel ...

Niktimvo™ (axatilimab-csfr) 4Q25 and full year 2025 net revenue, respectively; Syndax will report its share of the Niktimvo net profit when it reports full year 2025 results – – Ended 2025 with ...

As of Friday, January 09, Coherus Oncology, Inc.’s CHRS share price has surged by 6.86%, which has investors questioning if ...

PANTHERx® Rare Pharmacy, the trusted leader and innovator in patient access and support services for personalized rare ...

Under normal conditions, cytokines aid in pathogen recognition and elimination while contributing to immune system ...

Hong Kong, Shanghai Tuesday, January 6, 2026, 13:00 Hrs [IST] ...

Multiple sclerosis (MS) is a chronic neurological disease characterized by nerve damage and consequent impairments in vision, ...

HUTCHMED Initiates Phase III Stage of the Ongoing Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma Hong Kong, Shanghai & Florham Park, NJ — ...

Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, will ...

Program will expand access in certain regions where Revuforj is not available commercially, as permitted by local regulations -- Program will ...

Last Saturday (January 3th), a massive US military attack, concentrating the largest naval aggressor force ever assembled in ...